Diabetes Mellitus, Type 2
"Diabetes Mellitus, Type 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Descriptor ID |
D003924
|
| MeSH Number(s) |
C18.452.394.750.149 C19.246.300
|
| Concept/Terms |
Diabetes Mellitus, Type 2- Diabetes Mellitus, Type 2
- Diabetes Mellitus, Noninsulin-Dependent
- Diabetes Mellitus, Ketosis-Resistant
- Diabetes Mellitus, Ketosis Resistant
- Ketosis-Resistant Diabetes Mellitus
- Diabetes Mellitus, Non Insulin Dependent
- Diabetes Mellitus, Non-Insulin-Dependent
- Non-Insulin-Dependent Diabetes Mellitus
- Diabetes Mellitus, Stable
- Stable Diabetes Mellitus
- Diabetes Mellitus, Type II
- NIDDM
- Diabetes Mellitus, Noninsulin Dependent
- Diabetes Mellitus, Maturity-Onset
- Diabetes Mellitus, Maturity Onset
- Maturity-Onset Diabetes Mellitus
- Maturity Onset Diabetes Mellitus
- MODY
- Diabetes Mellitus, Slow-Onset
- Diabetes Mellitus, Slow Onset
- Slow-Onset Diabetes Mellitus
- Type 2 Diabetes Mellitus
- Noninsulin-Dependent Diabetes Mellitus
- Noninsulin Dependent Diabetes Mellitus
- Maturity-Onset Diabetes
- Diabetes, Maturity-Onset
- Maturity Onset Diabetes
- Type 2 Diabetes
- Diabetes, Type 2
- Diabetes Mellitus, Adult-Onset
- Adult-Onset Diabetes Mellitus
- Diabetes Mellitus, Adult Onset
|
Below are MeSH descriptors whose meaning is more general than "Diabetes Mellitus, Type 2".
Below are MeSH descriptors whose meaning is more specific than "Diabetes Mellitus, Type 2".
This graph shows the total number of publications written about "Diabetes Mellitus, Type 2" by people in this website by year, and whether "Diabetes Mellitus, Type 2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 20 | 0 | 20 |
| 1997 | 15 | 3 | 18 |
| 1998 | 5 | 3 | 8 |
| 1999 | 5 | 0 | 5 |
| 2000 | 23 | 6 | 29 |
| 2001 | 11 | 4 | 15 |
| 2002 | 13 | 5 | 18 |
| 2003 | 4 | 2 | 6 |
| 2004 | 16 | 4 | 20 |
| 2005 | 21 | 2 | 23 |
| 2006 | 22 | 3 | 25 |
| 2007 | 10 | 5 | 15 |
| 2008 | 19 | 8 | 27 |
| 2009 | 15 | 7 | 22 |
| 2010 | 19 | 4 | 23 |
| 2011 | 29 | 8 | 37 |
| 2012 | 22 | 7 | 29 |
| 2013 | 25 | 4 | 29 |
| 2014 | 39 | 6 | 45 |
| 2015 | 24 | 3 | 27 |
| 2016 | 32 | 5 | 37 |
| 2017 | 21 | 6 | 27 |
| 2018 | 25 | 6 | 31 |
| 2019 | 38 | 3 | 41 |
| 2020 | 16 | 8 | 24 |
| 2021 | 29 | 5 | 34 |
| 2022 | 37 | 1 | 38 |
| 2023 | 31 | 0 | 31 |
| 2024 | 21 | 5 | 26 |
| 2025 | 16 | 3 | 19 |
To return to the timeline,
click here.
Below are the most recent publications written about "Diabetes Mellitus, Type 2" by people in Profiles.
-
Comparative effectiveness of GLP-1 receptor agonists on cardiovascular outcomes among adults with type 2 diabetes and moderate cardiovascular risk: emulation of a target trial. Diabetes Res Clin Pract. 2025 Nov; 229:112910.
-
Comparative Risk of Adverse Pancreatic Events With GLP-1 Receptor Agonists, SGLT2 Inhibitors, DPP4 Inhibitors, and Sulfonylureas Among Adults With Type 2 Diabetes at Moderate Cardiovascular Disease Risk. Endocr Pract. 2026 Jan; 32(1):23-30.
-
Risk of Sight-Threatening Diabetic Retinopathy with Glucagon-Like Peptide-1 Receptor Agonist Use in Routine Clinical Practice: Comparative Effectiveness of Semaglutide, Dulaglutide, Liraglutide, and Exenatide. Ophthalmol Retina. 2026 Feb; 10(2):142-151.
-
Smaller Pancreas Volume in Insulin-Dependent Monogenic Diabetes. Diabetes. 2025 Aug 01; 74(8):1411-1416.
-
Heterogeneity of Cardiovascular Effects of Second-Line Glucose-Lowering Therapies in Adults With Type 2 Diabetes Across the Range of Moderate Baseline Cardiovascular Risk. J Am Heart Assoc. 2025 Aug 05; 14(15):e040217.
-
The 2018 World Cancer Research Fund/American Institute for Cancer Research Score and Cancer Risk: results from the diabetes prevention program outcomes study. Am J Clin Nutr. 2025 Sep; 122(3):715-723.
-
Approach to the Patient Using Diabetes Technology in Pregnancy. J Clin Endocrinol Metab. 2025 Jun 17; 110(7):e2317-e2326.
-
Reduced 90-Day Cardiovascular and Infectious Complications After Open Reduction Internal Fixation of Ankle Fractures in Type II Diabetic Patients Using Semaglutide Preoperatively. J Am Acad Orthop Surg. 2025 Jun 17; 33(16):e971-e978.
-
GLP-1R/GCGR dual agonism dissipates hepatic steatosis to restore insulin sensitivity and rescue pancreatic ß-cell function in obese male mice. Nat Commun. 2025 May 21; 16(1):4714.
-
scPrediXcan integrates deep learning methods and single-cell data into a cell-type-specific transcriptome-wide association study framework. Cell Genom. 2025 May 14; 5(5):100875.